Skip to main content

Advertisement

Table 1 Clinico-pathological parameters for patients with ET and early/prefibrotic PMF

From: Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis

  True ET PMF p value
M/F 27/34 26/46 n.s.
Median age (years) 58.0 (23–84) 55.5 (20–87) n.s.
Mean WBC (109/l) 7.5 8.4 p = 0.001
Mean Hb (g/dl) 14.1 14.3 n.s.
Mean PLT (109/l) 751 798 n.s.
Increased LDH (%) 17/45 (37.7%) 18/50 (36.0%) n.s.
Splenomegaly (%) 12 (19%) 18 (25%) n.s.
Mean semiquantitative score for granulopoiesis 0.15 1.02 p = 0.001
JAK2V617F-positive (%) 11 (33%) 23 (54%) n.s.
History of thrombosis (%) 5 (8%) 16 (22%) p = 0.032
Thrombosis at diagnosis (%) 1 (1.6%) 11 (15.2%) p = 0.006
Thrombotic events during follow up (%) 7 (11.4%) 11 (15.2%) n.s.
Progression to overt MF (%) 1 (1.6%) 3 (4.1%) n.s.
Dead/alive 2/59 8/64 n.s.
Conventional Risk (Low/High) 35/26 30/42 n.s.
Cytoreductive therapy (%) 51 (83%) 64 (88%) n.s.